# US 2020/0392177 A1 · Compositions and methods for treating cns disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392177 A1
- Document ID: US20200392177A1
- Status: Published application
- Kind: A1
- Application number: 16/748,117
- Filed: 2020-01-21
- Published: 2020-12-17
- Earliest claimed: 2014-10-16
- Assignees: Sage Therapeutics, Inc.
- Applicants: Sage Therapeutics, Inc.
- Inventors: Gabriel Martinez Botella; Francesco G. Salituro; Albert Jean Robichaud; Boyd L. Harrison
- Web page: https://patentgrep.com/patent/US20200392177A1

## CPC

- C07J 43/003: {not condensed}
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 23/00: Anaesthetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07J 9/00: Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J 1/0011: {substituted in position 17 by a keto group}
- C07J 1/0022: {the substituent being an OH group free esterified or etherified}
- C07J 3/005: {the carbon atom being part of a carboxylic function}
- C07J 5/0053: {not substituted in position 16}
- C07J 7/002: {not substituted in position 16}
- C07J 7/007: {not substituted in position 17 alfa}
- C07J 7/008: {substituted in position 21}
- C07J 11/00: Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
- C07J 13/007: {with double bond in position 17 (20)}
- C07J 21/00: Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J 31/006: {not covered by C07J31/003}
- C07J 41/0066: {the 17-beta position being substituted by a carbon atom forming part of an amide group}
- C07J 51/00: Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
- C07J 71/001: {Oxiranes}
- C07J: STEROIDS (seco-steroids C07C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein , A, R1, R2, R3a, R4a, R4b, R5, R7a, and R7b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.

## Claims

### Claim at position 1

1-73. (canceled)

### Claim 74

A compound of the Formula (I-a):
or a pharmaceutically acceptable salt thereof;
wherein:
Ring A is a substituted heterocyclyl linked through a nitrogen atom or a substituted heteroaryl linked through a nitrogen atom;
R1 is unsubstituted C1-3 alkyl, substituted C1-6 alkyl, haloalkyl, or alkoxyalkyl;
R2 is hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 carbocylyl, or —ORA2, wherein RA2 is hydrogen or substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, or substituted or unsubstituted C3-6 carbocylyl;
R3a is hydrogen or —ORA3, wherein RA3 is hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, or substituted or unsubstituted C3-6 carbocylyl, and R3b is hydrogen; or R3a and R3b are joined to form an oxo (═O) group;
R4a is hydrogen, substituted or unsubstituted C1-6 alkyl, or —ORA4, wherein RA4 is hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, or substituted or unsubstituted C3-6 carbocylyl, and R4b is hydrogen or substituted or unsubstituted C1-6 alkyl; or R4a and R4b are joined to form an oxo (═O) group; or R4a and R4b together with the carbon atom to which they are attached form a ring;
R5 is absent or hydrogen;
Each R6 is substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 carbocylyl, C1-6 haloalkyl, halogen, cyano, —ORA6, —C(═O)ORA6, —SRB6, —S(═O)RB6, S(═O)2RB6, nitro, N(RC6)(RD6), C(═O)N(RC6)(RD6), or N(RC6)C(═O)RA6;
wherein RA6 is hydrogen or substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 carbocylyl, or C1-6 haloalkyl; RB6 is substituted or unsubstituted C1-6 alkyl or substituted or unsubstituted C3-6 carbocylyl; and each of RC6 and RD6 is independently hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted aryl, or RC6 and RD6 together with the nitrogen atom to which they are attached form a 3-6-membered substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl ring;
n is 1, 2, or 3;
each of R7a and R7b is independently hydrogen or halogen;
is a single or double bond, wherein when one of is a double bond, the other is a single bond; and when one of the is a double bond, R5 and one of R7a and R7b is absent.

### Claim 75 (depends on 74)

The compound of claim 74, wherein is a single bond.

### Claim 76 (depends on 74)

The compound of claim 74, wherein R1 is substituted C1-3 alkyl, unsubstituted C1-3 alkyl, or alkoxyalkyl.

### Claim 77 (depends on 76)

The compound of claim 76, wherein R1 is substituted C1-3 alkyl or unsubstituted C1-3 alkyl.

### Claim 78 (depends on 76)

The compound of claim 76, wherein R1 is methyl, ethyl, propyl, or methoxymethyl.

### Claim 79 (depends on 78)

The compound of claim 78, wherein R1 is methyl.

### Claim 80 (depends on 74)

The compound of claim 74, wherein R2 is hydrogen, —ORA2, wherein RA2 is hydrogen, or substituted or unsubstituted C1-6 alkyl.

### Claim 81 (depends on 74)

The compound of claim 74, wherein R3a is —ORA3, wherein RA3 is hydrogen, or substituted or unsubstituted C1-6 alkyl (e.g., methyl).

### Claim 82 (depends on 74)

The compound of claim 74, wherein R4a is hydrogen, substituted C1-6 alkyl, or unsubstituted C1-6 alkyl.

### Claim 83 (depends on 74)

The compound of claim 74, wherein R4b is hydrogen, substituted C1-6 alkyl, or unsubstituted C1-6 alkyl.

### Claim 84 (depends on 74)

The compound of claim 74, wherein R4a is hydrogen, and R4b is substituted C1-6 alkyl or unsubstituted C1-6 alkyl.

### Claim 85 (depends on 74)

The compound of claim 74, wherein each of R4a and R4b is independently unsubstituted C1-6 alkyl.

### Claim 86 (depends on 74)

The compound of claim 74, wherein each of R4a and R4b is hydrogen.

### Claim 87 (depends on 74)

The compound of claim 74, wherein R5 is hydrogen.

### Claim 88 (depends on 74)

The compound of claim 74, wherein n is 1 and R6 is substituted or unsubstituted C1-6 alkyl, C1-6 haloalkyl, halogen, cyano, —ORA6, —C(═O)ORA6, —SRB6, —S(═O)RB6, or S(═O)2RB6, wherein RA6 is hydrogen, substituted or unsubstituted C1-6 alkyl, or C1-6 haloalkyl, and RB6 is substituted or unsubstituted C1-6 alkyl.

### Claim 89 (depends on 88)

The compound of claim 88, wherein n is 1 and R6 is halogen or cyano.

### Claim 90 (depends on 88)

The compound of claim 88, wherein n is 1 and R6 is substituted or unsubstituted C1-6 alkyl.

### Claim 91 (depends on 90)

The compound of claim 90, wherein n is 1 and R6 is methyl.

### Claim 92 (depends on 88)

The compound of claim 88, wherein n is 1 and R6 is C1-6 haloalkyl, —ORA6, or —C(═O)ORA6, wherein RA6 is hydrogen, substituted or unsubstituted C1-6 alkyl, or C1-6 haloalkyl

### Claim 93 (depends on 88)

The compound of claim 88, wherein n is 1 and R6 is SRB6, —S(═O)RB6, or —S(═O)2RB6, wherein RB6 is substituted or unsubstituted C1-6 alkyl.

### Claim 94 (depends on 74)

The compound of claim 74, wherein n is 2 and each R6 is independently selected from substituted or unsubstituted C1-6 alkyl, C1-6 haloalkyl, halogen, cyano, —ORA6, —C(═O)ORA6, —SRB6, —S(═O)RB6, and —S(═O)2RB6, wherein RA6 is hydrogen, substituted or unsubstituted C1-6 alkyl, or C1-6 haloalkyl, and RB6 is substituted or unsubstituted C1-6 alkyl.

### Claim 95 (depends on 94)

The compound of claim 94, wherein n is 2 and each R6 is independently selected from halogen.

### Claim 96 (depends on 74)

The compound of claim 74, wherein Ring A is selected from

### Claim 98 (depends on 74)

The compound of claim 74, wherein R1 is unsubstituted C1-3 alkyl and at least one of R2, R3a, R4a or R4b is not hydrogen.

### Claim 99 (depends on 74)

The compound of claim 74, wherein the compound of Formula (I-a) is a compound of Formula (II-a1):
or a pharmaceutically acceptable salt thereof; wherein Ring E is heteroaryl substituted with n instances of R6.

### Claim 100 (depends on 99)

The compound of claim 99, wherein
i) Ring E comprises at least two nitrogen atoms, or wherein ring E comprises at least two nitrogen atoms and at least one of R2, R3a, R4a or R4b is not hydrogen;
ii) Ring E comprises at least three nitrogen atoms, or wherein ring E comprises four nitrogen atoms;
iii) Ring E comprises 2, 3 or 4 nitrogen atoms, or wherein ring E is selected from pyrazole, triazole, tetrazole, indazole, benzotriazole, triazolopyridine, triazolopyrazine, or pyrazolopyrazine; or
iv) Ring E is a heteroaryl ring comprising at least 3 nitrogen atoms.

### Claim 101

A compound selected from
or a pharmaceutically acceptable salt thereof.

### Claim 102 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

### Claim 103 (depends on 1)

A method of inducing sedation and/or anesthesia in a subject, comprising administering to the subject in need thereof an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 104 (depends on 103)

The method of claim 103, wherein the subject experiences sedation and/or anesthesia within two hours of administration.

### Claim 105 (depends on 103)

The method of claim 103, wherein the compound is administered by intravenous administration.

### Claim 106 (depends on 103)

The method of claim 103, wherein the compound is administered chronically.

### Claim 107 (depends on 103)

The method of claim 103, wherein the subject is a mammal.

### Claim 108 (depends on 1)

A method for treating seizure in a subject, comprising administering to the subject an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 109 (depends on 1)

A method for treating epilepsy or status or status epilepticus in a subject, comprising administering to the subject an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 110 (depends on 109)

The method of claim 109, wherein the status epilepticus is convulsive status epilepticus selected from early status epilepticus, established status epilepticus, refractory status epilepticus, and super-refractory status epilepticus; the status epilepticus is non-convulsive status epilepticus selected from generalized status epilepticus and complex partial status epilepticus.

### Claim 111 (depends on 1)

A method for treating disorders related to GABA function in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 112 (depends on 111)

The method of claim 111, wherein the CNS-related disorder is a sleep disorder, a mood disorder, depression, a schizophrenia spectrum disorder, a convulsive disorder, a disorder of memory and/or cognition, a movement disorder, a personality disorder, autism spectrum disorder, pain, traumatic brain injury, a vascular disease, a substance abuse disorder and/or withdrawal syndrome, or tinnitus.

### Claim 113 (depends on 112)

The method of claim 112, wherein the compound or pharmaceutically acceptable salt thereof is administered orally.

### Claim 114 (depends on 112)

The method of claim 112, wherein the compound or pharmaceutically acceptable salt thereof is administered intramuscularly.
